1. (Original) A pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent, estramustine phosphate, a sulfoalkyl ether cyclodextrin and human albumin.

2. (Currently Amended) [[A]] The formulation according to claim 1 wherein the weight ratio of estramustine phosphate to the sulfoalkyl ether cyclodextrin is from about 1:0.5 to about 1:5.

3. (Currently Amended) [[A]] The formulation according to claim 1 which is in single infusion dosage from comprising at least 1300 mg, of the estramustine phosphate.

4. (Currently Amended) [[A]] The formulation according claim 1 which is in single infusion dosage form comprising at least 950 mg/m^2, of the estramustine phosphate.

5. (Currently Amended) [[A]] The formulation according to claim 1 wherein the sulfoalkyl ether cyclodextrin is a straight or branched C_1-C_6 sulfoalkyl ether cyclodextrin.

6. (Currently Amended) [[A]] The formulation according to claim 5 wherein the sulfoalkyl ether cyclodextrin is sulfobutyl ether ß-cyclodextrin.

7. (Canceled)

8. (Currently Amended) [[A]] The formulation according to claim 1 wherein the estramustine phosphate is in the form of a pharmaceutically acceptable salt for intravenous use.

9. (Currently Amended) [[A]] The formulation according to claim 8 wherein the estramustine phosphate is in the form of N-methyl glucamine salt.

10. (Currently Amended) A method for ~~formulation according to claim 1 for use in the~~ treatment of cancer comprising parenterally administering the formulation of claim 1 to a patient, whereby the cancer is treated .

11. (Currently Amended) ~~A formulation~~ The method as claimed in claim 10 wherein the cancer is prostate cancer, breast cancer, melanoma, lung cancer, pancreatic cancer, colorectal cancer, ovarian cancer or cancer of the brain.

12. (Canceled)

13. (Currently Amended) [[A]] The formulation according to claim 1 wherein
(i) the estramustine phosphate is in lyophilised form and the parenterally acceptable carrier or diluent is a physiological solution containing the sulfoalkyl ether cyclodextrin and the human albumin, or
(ii) the estramustine phosphate and sulfoalkyl ether cyclodextrin are in lyophilized form and the parenterally acceptable carrier or diluent is a physiological solution containing the human albumin.

14. (Original) A product which comprises
(i) a pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent and estramustine phosphate in admixture with a sulfoalkyl ether cyclodextrin and human albumin, and
(ii) one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy

15. (Currently Amended) [[A]] The product according to claim 14 wherein the sulfoalkyl ether cyclodextrin is sulfobutyl ether ß-cyclodextrin.

16. (Currently Amended) [[A]] The product according to claim 14 wherein the chemotherapeutic agent is selected from taxane, taxane derivatives, CPT-11, camptothecin and derivatives thereof, doxorubicin, idarubicin, epirubicin, etoposide, navelbine, vinblastine, carboplatin, cisplatin, Sugen SU 6668 and Sugen SU 5416.

17. (Canceled)

18. (Currently Amended) The method ~~A product~~ according to claim ~~14 for use in the treatment of~~ 14 26, wherein the cancer is prostate cancer, breast cancer, melanoma, lung cancer, pancreatic cancer, colorectal cancer, ovarian cancer or cancer of the brain.

19. (Currently Amended) A method of ~~A formulation as defined in claim 7 for use in~~ suppressing or reducing ~~the~~ side-effects associated with ~~the~~ intravenous administration of estramustine phosphate and pharmaceutically acceptable salts thereof comprising administering the formulation of claim 1 to a patient, whereby the side-effects are suppressed or reduced.

20. (Currently Amended) ~~A formulation~~ The method according to claim 19 wherein the side effects comprise ulcerative lesions and thrombophlebitis at the site of injection.

21. (Canceled)

22. (Canceled)

23. (Canceled)

24. (Canceled)

25. (New) A method for treatment of cancer comprising parenterally administering the product of claim 14 to a patient, whereby the cancer is treated.

26. (New) The method of claim 10, wherein the formulation is intravenously administered.

27. (New) The method of claim 26, wherein the product is intravenously administered.